BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

17752

530549

SHILPAMED

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

SHILPA MEDICARE LTD performance

Today’s low

Today’s high

₹ 644.00 ₹ 670.90
₹ 647.05

52 week low

52 week high

₹ 417.60 ₹ 959.50
₹ 647.05

Open Price

₹ 655.50

Prev. Close

₹ 664.45

Volume (Shares)

157418.00

Total traded value

₹ 1018.57

Upper Circuit

₹ 797.30

Lower Circuit

₹ 531.60

info

SHILPA MEDICARE LTD Share Price Update

As of the latest trading session, SHILPA MEDICARE LTD share price is currently at ₹ 647.05, which is down by ₹ -17.40 from its previous closing. Today, the stock has fluctuated between ₹ 644.00 and ₹ 670.90. Over the past year, SHILPA MEDICARE LTD has achieved a return of 17.57 %. In the last month alone, the return has been -1.55 %. Read More...

SHILPA MEDICARE LTD fundamentals


  • Market cap (Cr)

    5,616.51

  • P/E Ratio (TTM)

    111.61

  • Beta

    1.34

  • Book Value / share

    275.23

  • Return on equity

    1.59%

  • EPS (TTM)

    6.21

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    16.12

info icon alternate text
  • Market cap (Cr)

    5,609.13

  • P/E Ratio (TTM)

    111.61

  • Beta

    1.34

  • Book Value / share

    275.23

  • Return on equity

    1.59%

  • EPS (TTM)

    6.21

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    16.12

info icon alternate text

SHILPA MEDICARE LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 125.39
Operating Expense 116.39
Net Profit 16.12
Net Profit Margin (%) 12.85
Earnings Per Share (EPS) 1.65
EBITDA 38.91
Effective Tax Rate (%) 36.36
Particulars SEP 2024 (Values in Cr)
Revenue 129.68
Operating Expense 100.03
Net Profit 30.49
Net Profit Margin (%) 23.51
Earnings Per Share (EPS) 3.12
EBITDA 63.86
Effective Tax Rate (%) 39.80
Particulars JUN 2024 (Values in Cr)
Revenue 96.12
Operating Expense 86.42
Net Profit 28.35
Net Profit Margin (%) 29.49
Earnings Per Share (EPS) 2.94
EBITDA 54.94
Effective Tax Rate (%) 30.32
Particulars MAR 2024 (Values in Cr)
Revenue 59.36
Operating Expense 95.49
Net Profit -18.35
Net Profit Margin (%) -30.91
Earnings Per Share (EPS) -2.11
EBITDA -1.66
Effective Tax Rate (%) -10.14
Particulars DEC 2023 (Values in Cr)
Revenue 63.98
Operating Expense 82.28
Net Profit 2.70
Net Profit Margin (%) 4.22
Earnings Per Share (EPS) 0.31
EBITDA 18.91
Effective Tax Rate (%) 30.94
Particulars MAR 2024 (Values in Cr)
Revenue 309.79
Operating Expense 350.37
Net Profit 26.94
Net Profit Margin (%) 8.69
Earnings Per Share (EPS) 3.10
EBITDA 104.96
Effective Tax Rate (%) 29.27
Particulars MAR 2023 (Values in Cr)
Revenue 247.70
Operating Expense 359.08
Net Profit 57.19
Net Profit Margin (%) 23.08
Earnings Per Share (EPS) 6.59
EBITDA 9.09
Effective Tax Rate (%) 15.08
Particulars MAR 2022 (Values in Cr)
Revenue 356.95
Operating Expense 379.13
Net Profit 140.99
Net Profit Margin (%) 39.49
Earnings Per Share (EPS) 16.87
EBITDA 71.36
Effective Tax Rate (%) 26.66
Particulars MAR 2021 (Values in Cr)
Revenue 257.05
Operating Expense 252.03
Net Profit 184.39
Net Profit Margin (%) 71.73
Earnings Per Share (EPS) 7.98
EBITDA 118.56
Effective Tax Rate (%) 27.84
Particulars MAR 2020 (Values in Cr)
Revenue 805.97
Operating Expense 600.35
Net Profit 193.72
Net Profit Margin (%) 24.03
Earnings Per Share (EPS) 23.76
EBITDA 251.63
Effective Tax Rate (%) 20.79
Particulars MAR 2024 (Values in Cr)
Book Value / Share 208.37
ROE % 1.72
ROCE % 5.16
Total Debt to Total Equity 0.48
EBITDA Margin 21.48
Particulars MAR 2023 (Values in Cr)
Book Value / Share 205.44
ROE % -1.72
ROCE % 0.79
Total Debt to Total Equity 0.41
EBITDA Margin 11.03
Particulars MAR 2022 (Values in Cr)
Book Value / Share 209.93
ROE % 3.67
ROCE % 5.84
Total Debt to Total Equity 0.46
EBITDA Margin 19.49
Particulars MAR 2021 (Values in Cr)
Book Value / Share 181.37
ROE % 7.20
ROCE % 7.58
Total Debt to Total Equity 0.44
EBITDA Margin 23.38
Particulars MAR 2020 (Values in Cr)
Book Value / Share 163.06
ROE % 12.23
ROCE % 12.04
Total Debt to Total Equity 0.23
EBITDA Margin 26.04
Particulars MAR 2024 (Values in Cr)
Book Value / Share 246.85
ROE % 1.59
ROCE % 2.77
Total Debt to Total Equity 0.10
EBITDA Margin 37.06
Particulars MAR 2023 (Values in Cr)
Book Value / Share 243.96
ROE % 3.49
ROCE % -0.84
Total Debt to Total Equity 0.12
EBITDA Margin 10.08
Particulars MAR 2022 (Values in Cr)
Book Value / Share 237.97
ROE % 7.17
ROCE % 1.10
Total Debt to Total Equity 0.23
EBITDA Margin 17.57
Particulars MAR 2021 (Values in Cr)
Book Value / Share 200.89
ROE % 8.93
ROCE % 2.09
Total Debt to Total Equity 0.33
EBITDA Margin 25.61
Particulars MAR 2020 (Values in Cr)
Book Value / Share 178.27
ROE % 14.17
ROCE % 14.53
Total Debt to Total Equity 0.21
EBITDA Margin 34.39
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 30.43
Total Assets 3093.20
Total Liabilities 3093.20
Total Equity 1799.95
Share Outstanding 86801898
Price to Book Ratio 1.87
Return on Assets (%) 1.03
Return on Capital (%) 1.17
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 21.56
Total Assets 2903.92
Total Liabilities 2903.92
Total Equity 1774.35
Share Outstanding 86801898
Price to Book Ratio 0.94
Return on Assets (%) -1.12
Return on Capital (%) -1.27
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 34.11
Total Assets 2875.49
Total Liabilities 2875.49
Total Equity 1811.14
Share Outstanding 86801898
Price to Book Ratio 1.67
Return on Assets (%) 2.10
Return on Capital (%) 2.43
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 123.10
Total Assets 2632.36
Total Liabilities 2632.36
Total Equity 1467.49
Share Outstanding 81526899
Price to Book Ratio 1.66
Return on Assets (%) 5.61
Return on Capital (%) 6.39
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 44.56
Total Assets 1989.20
Total Liabilities 1989.20
Total Equity 1321.45
Share Outstanding 81526899
Price to Book Ratio 1.37
Return on Assets (%) 7.85
Return on Capital (%) 9.45
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 3.12
Total Assets 2418.58
Total Liabilities 2418.58
Total Equity 2142.71
Share Outstanding 86801898
Price to Book Ratio 1.87
Return on Assets (%) 1.11
Return on Capital (%) 1.18
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 4.82
Total Assets 2518.65
Total Liabilities 2518.65
Total Equity 2117.58
Share Outstanding 86801898
Price to Book Ratio 0.94
Return on Assets (%) 2.27
Return on Capital (%) 2.38
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 15.83
Total Assets 2896.11
Total Liabilities 2896.11
Total Equity 2065.66
Share Outstanding 86801898
Price to Book Ratio 1.67
Return on Assets (%) 4.86
Return on Capital (%) 6.24
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 115.27
Total Assets 2517.39
Total Liabilities 2517.39
Total Equity 1637.83
Share Outstanding 81526899
Price to Book Ratio 1.66
Return on Assets (%) 7.32
Return on Capital (%) 8.05
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 28.18
Total Assets 2021.28
Total Liabilities 2021.28
Total Equity 1453.42
Share Outstanding 81526899
Price to Book Ratio 1.37
Return on Assets (%) 9.58
Return on Capital (%) 10.92
Particulars MAR 2024 (Values in Cr)
Net Income 54.34
Cash from Operations 176.49
Cash from Investing -166.58
Cash from Financing 46.77
Net change in Cash 15.52
Free Cash Flow 361.05
Particulars MAR 2023 (Values in Cr)
Net Income -38.27
Cash from Operations 212.29
Cash from Investing -232.61
Cash from Financing 45.79
Net change in Cash -6.89
Free Cash Flow 438.96
Particulars MAR 2022 (Values in Cr)
Net Income 102.26
Cash from Operations 139.61
Cash from Investing -285.49
Cash from Financing 82.85
Net change in Cash -97.50
Free Cash Flow 471.44
Particulars MAR 2021 (Values in Cr)
Net Income 195.05
Cash from Operations 94.52
Cash from Investing -404.27
Cash from Financing 436.37
Net change in Cash 79.02
Free Cash Flow 448.77
Particulars MAR 2020 (Values in Cr)
Net Income 188.05
Cash from Operations 166.57
Cash from Investing -289.51
Cash from Financing 175.50
Net change in Cash 10.36
Free Cash Flow 515.85
Particulars MAR 2024 (Values in Cr)
Net Income 38.08
Cash from Operations 14.98
Cash from Investing 155.82
Cash from Financing -163.07
Net change in Cash 0.78
Free Cash Flow 70.06
Particulars MAR 2023 (Values in Cr)
Net Income 12.67
Cash from Operations 10.49
Cash from Investing -94.83
Cash from Financing 87.67
Net change in Cash -5.07
Free Cash Flow 68.76
Particulars MAR 2022 (Values in Cr)
Net Income 192.89
Cash from Operations 208.36
Cash from Investing -378.97
Cash from Financing 97.22
Net change in Cash -107.87
Free Cash Flow 381.81
Particulars MAR 2021 (Values in Cr)
Net Income 255.53
Cash from Operations 112.97
Cash from Investing -238.13
Cash from Financing 255.57
Net change in Cash 87.07
Free Cash Flow 378.68
Particulars MAR 2020 (Values in Cr)
Net Income 233.98
Cash from Operations 170.64
Cash from Investing -295.09
Cash from Financing 170.10
Net change in Cash 4.80
Free Cash Flow 250.61
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

SHILPA MEDICARE LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
647.05 -2.61 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 666.70
  • 26 Days 664.80
  • 10 Days 668.10
  • 50 Days 675.50
  • 12 Days 667.40
  • 100 Days 702.20
  • 20 Days 665.00
  • 200 Days 693.30
670.57 PIVOT

First Support

655.38

First Resistance

679.63

Second Support

646.32

Second Resistance

694.82

Third Support

631.13

Third Resistance

703.88

RSI

46.30

ADX

13.70

MACD

2.58

Williams % R

-67.53

Commodity Channel Index (CCI)

-17.25

Date

2025-04-30

Week

72579.00

Same Day

72951.00

Month

74163.00

1 Year

1.35

3 Year

1.00

Over 1 Month

-1.55%

down

Over 1 Year

17.57%

down

Over 3 Months

-8.25%

down

Over 3 Years

12.50%

down

Over 6 Months

-23.39%

down

Over 5 Years

12.19%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

SHILPA MEDICARE LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
37.25%
Promoter Holdings
44.22%
FII
10.97%
DII
7.54%
Promoter Shares(Pledge Percentage)
7.92%
Name Shares Category
Vishnukant Chaturbhuj Bhutada 6365610.0 (6.51%) Shareholding of Promoter and Promoter Group
Dharmavati Bhutada 6207796.0 (6.35%) Shareholding of Promoter and Promoter Group
Ravi Kumar Innani 4006370.0 (4.1%) Shareholding of Promoter and Promoter Group
Suraj Kumar Inani 3920695.0 (4.01%) Shareholding of Promoter and Promoter Group
Om Prakash Inani 2867691.0 (2.93%) Shareholding of Promoter and Promoter Group
Deepak Kumar Innani 2733960.0 (2.8%) Shareholding of Promoter and Promoter Group
Kantadevi Inani 2540096.0 (2.6%) Shareholding of Promoter and Promoter Group
Pivotal Enterprises Private Limited 2200000.0 (2.25%) Public Shareholding
Cohesion Mk Best Ideas Sub-trust 2126137.0 (2.17%) Public Shareholding
Madhav Vishnukant Bhutada 2000000.0 (2.05%) Shareholding of Promoter and Promoter Group
Keshav Bhutada 2000000.0 (2.05%) Shareholding of Promoter and Promoter Group
Icici Prudential Elss Tax Saver Fund 1996117.0 (2.04%) Public Shareholding
Sbi Life Insurance Co. Ltd 1712086.0 (1.75%) Public Shareholding
Ramakant Innani 1497778.0 (1.53%) Shareholding of Promoter and Promoter Group
Akash Bhanshali 1490094.0 (1.52%) Public Shareholding
Dovetail India Fund Class 6 Shares 1486066.0 (1.52%) Public Shareholding
Bandhan Small Cap Fund 1422283.0 (1.45%) Public Shareholding
Vishnukanth C Bhutada (huf) 1336130.0 (1.37%) Shareholding of Promoter and Promoter Group
Taradevi Innani 1249998.0 (1.28%) Shareholding of Promoter and Promoter Group
Vishnukanta Inani 1212498.0 (1.24%) Shareholding of Promoter and Promoter Group
Elm Park Fund Limited 1200000.0 (1.23%) Public Shareholding
Brijgopal Innani 1174866.0 (1.2%) Shareholding of Promoter and Promoter Group
Natamal Innani 1131232.0 (1.16%) Shareholding of Promoter and Promoter Group
Shakuntalabai Innani 1129186.0 (1.15%) Shareholding of Promoter and Promoter Group
Sapphire Intrex Limited 1066566.0 (1.09%) Public Shareholding
Viral Parikh 1000000.0 (1.02%) Public Shareholding
Sagar Innani 1000000.0 (1.02%) Shareholding of Promoter and Promoter Group
Triveni Inani 294810.0 (0.3%) Shareholding of Promoter and Promoter Group
Kamalkishore Innani 165236.0 (0.17%) Shareholding of Promoter and Promoter Group
Keerti Innani 155021.0 (0.16%) Shareholding of Promoter and Promoter Group
Manjulatha Innani 157546.0 (0.16%) Shareholding of Promoter and Promoter Group
Priya Inani 80696.0 (0.08%) Shareholding of Promoter and Promoter Group
Namrata Bhutada 22500.0 (0.02%) Shareholding of Promoter and Promoter Group
Dbs Bank India Limited - Foreign Scheduled Commercial Bank 1500.0 (0.0%) Public Shareholding

News

Left Arrow
Right Arrow

SHILPA MEDICARE LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
19 Sep 2022 1.1 Final 20 Sep 2022 Equity shares
20 Sep 2021 1.1 Final 22 Sep 2021 Equity shares
16 Mar 2020 1.1 Interim 17 Mar 2020 Equity shares
12 Sep 2019 1.0 Final 14 Sep 2019 Equity shares
01 Mar 2018 0.7 Interim 05 Mar 2018 Equity shares
21 Mar 2017 0.6 Interim 22 Mar 2017 Equity shares
28 Mar 2016 0.6 Interim 29 Mar 2016 Equity shares
16 Sep 2015 1.1 Final 21 Sep 2015 Equity shares
11 Sep 2014 1.0 Final 13 Sep 2014 Equity shares
16 Jul 2013 1.3 Final 18 Jul 2013 Equity shares
17 Sep 2012 0.9 Final 19 Sep 2012 Equity shares
15 Sep 2011 0.8 Final 19 Sep 2011 Equity shares
16 Sep 2010 0.7 Final 20 Sep 2010 Equity shares
24 Sep 2009 0.5 Final 26 Sep 2009 Equity shares
11 Sep 2008 0.4 Final 15 Sep 2008 Equity shares
24 May 2007 2.0 Interim 26 May 2007 Equity shares
26 Sep 2005 0.0 Final 27 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
18 Jul 2013 16 Jul 2013 1:2
Ex-Date Old FV NEW FV Record Date
06 Nov 2015 2.0 1.0 09 Nov 2015
28 Sep 2007 10.0 2.0 08 Oct 2007
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
19 Sep 2022 1.1 Final 20 Sep 2022 Equity shares
20 Sep 2021 1.1 Final 22 Sep 2021 Equity shares
16 Mar 2020 1.1 Interim 17 Mar 2020 Equity shares
12 Sep 2019 1.0 Final 14 Sep 2019 Equity shares
01 Mar 2018 0.7 Interim 05 Mar 2018 Equity shares
21 Mar 2017 0.6 Interim 22 Mar 2017 Equity shares
28 Mar 2016 0.6 Interim 29 Mar 2016 Equity shares
16 Sep 2015 1.1 Final 21 Sep 2015 Equity shares
11 Sep 2014 1.0 Final 13 Sep 2014 Equity shares
16 Jul 2013 1.3 Final 18 Jul 2013 Equity shares
17 Sep 2012 0.9 Final 19 Sep 2012 Equity shares
15 Sep 2011 0.8 Final 19 Sep 2011 Equity shares
16 Sep 2010 0.7 Final 20 Sep 2010 Equity shares
24 Sep 2009 0.5 Final 26 Sep 2009 Equity shares
11 Sep 2008 0.4 Final 15 Sep 2008 Equity shares
24 May 2007 2.0 Interim 26 May 2007 Equity shares
26 Sep 2005 0.0 Final 27 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
18 Jul 2013 16 Jul 2013 1:2
Ex-Date Old FV NEW FV Record Date
06 Nov 2015 2.0 1.0 09 Nov 2015
28 Sep 2007 10.0 2.0 08 Oct 2007

SHILPA MEDICARE LTD Share Price

Shilpa Medicare Limited (Formerly known as Shilpa Antibiotics Private Limited) was incorporated as a Private Limited Company on November 20, 1987. The Company changed the status to Public Limited and the name of the Company was changed to Shilpa Antibiotics Limited in November, 1993 and later on, was changed to 'Shilpa Medicare Limited' on February 17, 2003.

The Company has been promoted by Vishnukant C. Bhutada and his Associates and is engaged in manufacturing of API, Formulation and Development service. The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka. It then started commercial production in November, 1989.

The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology. It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. While SML's underlying expertise is in the field of oncology, it also derives revenue from sale of non-oncology APIs. With key products being Ambroxol (Mucolytic Agent) in Europe and Tranexmic Acid and Ursodeoxycholic Acid in India.

SML deals in high-quality Active Pharmaceutical Ingredients (APIs), Bulk drug, Intermediates, Formulations and Development service, New Drug Delivery Systems, Peptides / Biotech products and Specialty Chemicals etc. using sophisticated technology meticulously in order to comply with laid down international standards/specifications. SML is among the world's leading suppliers of Oncology/Non-Oncology APIs and intermediates.

In year 1992, the company installed production facilities to manufacture sodium methoxide.

During FY 2015, projects of five products transfer executed successfully, other projects of eight products have been completed and ready for transfer to plant. Ten new molecules have been taken for development considering future demand.

During FY15, as part of mobilization of resources for the purpose of expanding the operations of the Company, fresh funds were raised by allotting 17,64,705 equity shares of Rs.2/- each to Tano Mauritius India FVCI II, the existing member of the Company, at a premium of Rs 423/-each on 15 May 2014 on preferential basis.

During FY2016, the company after obtaining the approval of members at the 28th Annual General Meeting held on 28 September, 2015, divided the face value of existing equity share of Rs.2/- into two equity shares of Re.1/- each fully paid-up, with effect from the Record Date specified.

Raichem Medicare Pvt Ltd., a subsidiary of Shilpa Medicare, completed installation of all machineries during the FY 2015-2016 and recruited all the key personnel, also commenced trial production in August 2015 after the Audit by External Consultant from Italy and started commercial production in December-2015. The subsidiary obtained the Drug Manufacturing license and GMP certificate and consent from pollution control board for operating the plant.

In FY 16-17, Shilpa Medicare launched the generic versions of Vidaza Injection & Xeloda Tablets. During the year under review, as part of mobilization of resources for the purpose of expanding the operations of the company, fresh funds were raised by allotting 30,25,000 equity shares of Re.1/- each to TA FII Investors Limited, at a premium of Rs.569/- each on 26 December, 2016 on preferential basis.

Pursuant to the order dated 24 November 2017 of Hon'ble National Company Law Tribunal, Bangalore Bench, the Navya Biologicals Private Limited was merged with the Company effective from 1 April, 2016.

In FY 2019, the company incorporated Shilpa Pharma Inc. as a wholly owned subsidiary in USA.

During the current FY 2019-20, the Company formed Sravathi Advance Process Technologies Private Limited to foray into the R&D activities of specific drug processes by roping prominent technocrats. It launched the Indian branded generic of Ibrutinib, an anti-cancer drug under the brand name 'IBRUSHIL'.

During the financial year 2019-2020, Shilpa launched Azacitidine, covering the majority of European countries. It launched the first Indian Branded Generic of Lenvatinib Mesylate under the brand name Lenshil which is used for the treatment of differentiated thyroid cancer (DTC) and hepatocellular carcinoma. It sold 26% stake and exited from in Raichem Medicare Private Limited, erstwhile Joint Venture, in the month of June, 2020. It incorporated Shilpa Albumin Private Limited and Shilpa Biologicals Private Limited as Wholly Owned Subsidiaries of the Company.

In 2021, the Company launched a pediatric dose paracetamol oral thin film, under the brand name 'Molshil' in strengths of 60 mg and 120 mg. It commissioned the State of Art Centralized Finished Dosages R&D Centre at Dabaspet near Bangalore.

In 2021, Shilpa Biologicals Pvt Ltd, (SBPL), a wholly owned subsidiary of Company signed an agreement with Dr. Reddy's Laboratories for production-supply of Sputnik V vaccine from its integrated Biologics R&D cum manufacturing center at Dharwad, Karnataka. It formed Sravathi AI Technology Private Limited, Shilpa Corporate Holdings Private Limited and Koanna Helathcare, Cananda.

In FY 2022, the Company commissioned a combo line for ODF/TDS.

During the year 2021-22, Shilpa Corporate holdings Private Limited an investment company, has been formed as a wholly owned
subsidiary, which acquired 100% stake in FTF Pharma Private Limited an an integrated drug development company, Koanaa Healthcare Canada, Koanaa International FZ LLC (Dubai), Indo Biotech SDN. BHD Malaysia, and so that all these companies have become as wholly Owned Subsidiaries. Further, the Company acquired balance 25% equity shares of INM Technologies Private Limited and made a wholly owned subsidiary. INM Technologies Private Limited which is the wholly owned subsidiary of the Company holds 25% of its stake in INM Nuvent Paints Private Limited. The Company had disposed off the total stake in Loba Feinchemie Gmbh, a step down subsidiary in Austria.

In 2022, the Company launched 12 formulations in India. The new launches were in the therapeutic areas of oncology, non-oncology, and products for the OTC market such as women hygiene, vitamin supplements and an antioxidant green tea film. It commissioned new R&D center for polymer & peptide, created separate wing for CDMO.

Parent organization Indian Private
NSE symbol SHILPAMED
Founded 1987
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Shilpa Medicare Ltd?

Answer Field

The share price of Shilpa Medicare Ltd for NSE is ₹ 647.05 and for BSE is ₹ 646.2.

What is the Market Cap of Shilpa Medicare Ltd?

Answer Field

The market cap of Shilpa Medicare Ltd for NSE is ₹ 56,16.51 Cr. and for BSE is ₹ 56,09.13 Cr. as of now.

What is the 52 Week High and Low of Shilpa Medicare Ltd?

Answer Field

The 52 Week High and Low of Shilpa Medicare Ltd for NSE is ₹ 959.50 and ₹ 417.60 and for BSE is ₹ 959.95 and ₹ 419.10.

How to Buy Shilpa Medicare Ltd share?

Answer Field

You can trade in Shilpa Medicare Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Shilpa Medicare Ltd?

Answer Field

The 1 year returns on the stock has been 17.57%.

What is the Current Share Price of Shilpa Medicare Ltd?

Answer Field

Shilpa Medicare Ltd share price is for NSE ₹ 647.05 & for BSE ₹ 646.2 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Shilpa Medicare Ltd Share?

Answer Field

The market cap of Shilpa Medicare Ltd for NSE ₹ 56,16.51 & for BSE ₹ 56,09.13 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Shilpa Medicare Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Shilpa Medicare Ltd share is 111.61.

What is the PB ratio of Shilpa Medicare Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Shilpa Medicare Ltd share is 275.23.

How to Buy Shilpa Medicare Ltd Share?

Answer Field

You can trade in Shilpa Medicare Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Shilpa Medicare Ltd Share on Bajaj Broking App?

Answer Field

To buy Shilpa Medicare Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Shilpa Medicare Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|